This site uses cookies to bring you the best experience. Find out more
Skip to main content


Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on if you would like to know more about any of these stories.

You can also follow us on X or LinkedIn  

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

- EXS4318 is the first immunology & inflammation candidate designed by Exscientia and its fourth molecule to enter the clinic - - Exscientia invented a potentially first-in-class potent and selective PKC theta inhibitor - - Eligible for pre-commercial milestone payments and, if approved, tiered royalties on net product sales - OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a... Read more


– Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC –  BERGEN, Norway, February 2, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the formation of a scientific advisory board consisting of four world-renowned non-small cell lung cancer (NSCLC) experts from top oncology... Read more

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company dedicated to creating first-in-class therapeutics for cachexia caused by cancer and other chronic conditions, with its lead compound having proven safe and well-tolerated in its Phase 1 trials. The collaboration aims to accelerate Endevica’s... Read more

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

Scancell Holdings Plc (“Scancell” or the “Company”) Directorate Change Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board Jean-Michel brings 25 years of experience in the international pharmaceutical and biotech industries both in an executive and non-executive capacity Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today... Read more

Ellison Institute Submits Planning Application for Oxford Campus

The new science research facility’s purposeful design promotes collaboration and interdisciplinary research, incorporating laboratories, a patient clinic, and educational spaces, with exemplar Environmental, Social, & Governance credentials at its heart Oxford, UK – 30 January 2023 – The Lawrence J. Ellison Institute for Transformative Medicine submitted a planning application to Oxford City Council for a new research and development facility... Read more

The Daubeny Project

Imaginative design, inspiring spaces.